NR3C1 and benign prostatic hyperplasia: The relative expression of AR-FL, AR-V7, and GR mRNAs in tissue samples from individual patients with CRPC (AR-targeting therapy: n=38; taxane chemotherapy: n=14), BPH (n=2), and hormone-naïve cancer (n=6) is shown in Figure S1.